EUVIMEDEUVIMED entdecken
Open Access

Interplay of Atherogenic Particle Number and Particle Size and the Risk of Coronary Heart Disease

Karol M Pencina, Michael J Pencina, Patrick R Lawler iD, James C Engert, Line Dufresne, Paul M Ridker iD, George Thanassoulis, Samia Mora, Allan D Sniderman

Clinical Chemistry · 2023

DOI: 10.1093/clinchem/hvac172 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Chemistry, 2023. Verfasst von Karol M Pencina und 8 weiteren Autor:innen. Beteiligte Einrichtung: Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Hauptthemen laut MEDLINE: Coronary Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NHLBI NIH HHS, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We examined the interplay of apolipoprotein B (apoB) and LDL particle size, approximated by the LDL-cholesterol (LDL-C)/apoB ratio, on the risk of new-onset coronary heart disease (CHD).

Methods

Participants without cardiovascular disease from the UK Biobank (UKB; n = 308 182), the Women’s Health Study (WHS; n = 26 204), and the Framingham Heart Study (FHS; n = 2839) were included. Multivariable Cox models were used to assess the relationship between apoB and LDL-C/apoB ratio and incidence of CHD (14 994 events). Our analyses were adjusted for age, sex (except WHS), HDL-cholesterol (HDL-C), systolic blood pressure, antihypertensive treatment, diabetes, and smoking.

Results

In all 3 studies, there was a strong positive correlation between apoB and LDL-C (correlation coefficients r = 0.80 or higher) and a weak inverse correlation of apoB with LDL-C/apoB ratio (−0.28 ≤ r ≤ −0.14). For all 3 cohorts, CHD risk was higher for higher levels of apoB. Upon multivariable adjustment, the association between apoB and new-onset CHD remained robust and statistically significant in all 3 cohorts with hazard ratios per 1 SD (95% CI): 1.24 (1.22–1.27), 1.33 (1.20–1.47), and 1.24 (1.09–1.42) for UKB, WHS, and FHS, respectively. However, the association between LDL-C/apoB and CHD was statistically significant only in the FHS cohort: 0.78 (0.64–0.94).

Conclusions

Our analysis confirms that apoB is a strong risk factor for CHD. However, given the null association in 2 of the 3 studies, we cannot confirm that cholesterol-depleted LDL particles are substantially more atherogenic than cholesterol-replete particles. These results lend further support to routine measurement of apoB in clinical care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coronary DiseaseHumansFemaleCholesterol, LDLParticle SizeApolipoproteins BCholesterolRisk FactorsCholesterol, HDL

Stichwörter der Autor:innen

LDL-C/apoBapoBcoronary heart disease risk

Substanzen

Cholesterol, LDLApolipoproteins BCholesterolCholesterol, HDL

Autor:innen und Institutionen

  • Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • North Carolina Department of Laboratory Medicine, Duke University School of Medicine, Biostatistics and Bioinformatics, DCRI, Durham, NC 27614, USA.
  • Peter Munk Cardiac Centre, Toronto General Hospital, University of Toronto, Toronto, Ontario M5G 2C4, Canada.
  • Research Institute of the McGill University Health Centre, Montreal, Quebec H4A 3J1, Canada.
  • Mike and Valeria Rosenbloom Centre for Cardiovascular Prevention, Department of Medicine, McGill University Health Centre, Montreal, Quebec H4A 3J1, Canada.
  • Department of Medicine, Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA.

ORCID-Profile: Patrick R Lawler, Paul M Ridker

Förderung

  • NCI NIH HHS
  • NHLBI NIH HHS
  • Medical Research Council
  • NIH HHS
  • National Institutes of Health
  • National Heart, Lung, and Blood Institute
  • Heart and Stroke Foundation of Canada

Zitieren

APA

Pencina, K. M., Pencina, M. J., Lawler, P. R., Engert, J. C., Dufresne, L., Ridker, P. M., Thanassoulis, G., Mora, S., & Sniderman, A. D. (2023). Interplay of Atherogenic Particle Number and Particle Size and the Risk of Coronary Heart Disease. Clinical Chemistry. https://doi.org/10.1093/clinchem/hvac172

Vancouver

Pencina KM, Pencina MJ, Lawler PR, Engert JC, Dufresne L, Ridker PM, et al. Interplay of Atherogenic Particle Number and Particle Size and the Risk of Coronary Heart Disease. Clinical Chemistry. 2023. doi:10.1093/clinchem/hvac172

BibTeX
@article{Pencina2023,
  author = {Pencina, Karol M and Pencina, Michael J and Lawler, Patrick R and Engert, James C and Dufresne, Line and Ridker, Paul M and Thanassoulis, George and Mora, Samia and Sniderman, Allan D},
  title = {Interplay of Atherogenic Particle Number and Particle Size and the Risk of Coronary Heart Disease},
  journal = {Clinical Chemistry},
  year = {2023},
  doi = {10.1093/clinchem/hvac172}
}
Kostenlos starten →